Halozyme Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 8, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Cap	9,533	7,927	5,887	4,685	7,690	5,529
Market Cap Growth	46.50%	34.64%	25.65%	-39.07%	39.09%	-4.70%
Enterprise Value	11,391	9,927	6,797	5,849	8,834	5,665
Last Close Price	80.37	67.30	47.81	36.96	56.90	40.21
PE Ratio	28.29	26.29	13.94	17.60	39.51	14.68
Forward PE	9.12	8.85	10.38	9.77	21.92	17.89
PS Ratio	6.32	5.68	5.80	5.65	11.65	12.47
PB Ratio	43.37	162.39	16.18	55.91	45.29	28.07
P/TBV Ratio	-	-	-	-	-	29.97
P/FCF Ratio	14.28	12.30	12.57	12.55	32.68	18.55
P/OCF Ratio	14.07	12.17	12.29	12.06	32.03	18.46
EV/Sales Ratio	7.55	7.11	6.69	7.05	13.38	12.78
EV/EBITDA Ratio	11.95	17.82	10.74	13.85	27.85	20.31
EV/EBIT Ratio	13.26	21.17	12.33	17.33	33.02	20.53
EV/FCF Ratio	17.06	15.40	14.51	15.67	37.54	19.01
Debt / Equity Ratio	8.81	43.89	4.14	17.89	8.79	4.00
Debt / EBITDA Ratio	3.50	3.85	2.38	3.55	4.75	3.14
Debt / FCF Ratio	3.21	3.32	3.22	4.02	6.40	2.94
Net Debt / Equity Ratio	8.31	40.97	2.50	13.88	6.73	0.69
Net Debt / EBITDA Ratio	2.98	3.59	1.44	2.75	3.61	0.49
Net Debt / FCF Ratio	2.74	3.10	1.94	3.12	4.86	0.46
Asset Turnover	0.58	0.61	0.53	0.46	0.45	0.53
Inventory Turnover	1.56	1.44	1.18	1.69	1.81	1.42
Quick Ratio	2.14	3.30	6.50	5.07	4.54	7.10
Current Ratio	2.76	4.66	7.80	6.64	5.65	7.91
Return on Equity (ROE)	259.89%	153.59%	198.42%	222.07%	110.23%	231.44%
Return on Assets (ROA)	13.65%	13.87%	23.16%	15.27%	14.75%	53.09%
Return on Invested Capital (ROIC)	17.33%	19.16%	34.88%	21.32%	26.40%	174.31%
Return on Capital Employed (ROCE)	21.98%	21.95%	31.11%	20.27%	19.83%	48.16%
Earnings Yield	3.66%	3.80%	7.17%	5.68%	2.53%	6.81%
FCF Yield	7.00%	8.13%	7.96%	7.97%	3.06%	5.39%
Buyback Yield / Dilution	4.58%	4.27%	3.56%	4.56%	4.22%	-3.77%
Total Shareholder Return	4.58%	4.27%	3.56%	4.56%	4.22%	-3.77%

SEC Filings: 10-K · 10-Q